Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neurometabolic disease

H W Moser1

  • 1Kennedy Krieger Institute, Baltimore, MD 21205, USA.

Current Opinion in Neurology
|April 29, 1998
PubMed
Summary
This summary is machine-generated.

Neurometabolic disease research advances with defined molecular defects in Niemann-Pick C and peroxisome biogenesis disorders. Promising therapies and animal models are emerging for conditions like Pelizaeus Merzbacher disease and X-linked adrenoleukodystrophy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A PEX10 defect in a patient with no detectable defect in peroxisome assembly or metabolism in cultured fibroblasts.

Journal of inherited metabolic disease·2009
Same author

Magnetization transfer MRI demonstrates spinal cord abnormalities in adrenomyeloneuropathy.

Neurology·2005
Same author

Spectroscopic evidence of cerebral axonopathy in patients with "pure" adrenomyeloneuropathy.

Neurology·2005
Same author

Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy.

Neurology·2003
Same author

Clinical and electrophysiological improvement of adrenomyeloneuropathy with steroid treatment.

Journal of neurology, neurosurgery, and psychiatry·2003
Same author

MRI and proton MRSI in women heterozygous for X-linked adrenoleukodystrophy.

Neurology·2003
Same journal

Movement disorders and Parkinson's disease: collaborative and interdisciplinary research to advance understanding of neural circuit dysfunction, pathophysiology, and care: new horizons in technology, neuroimaging, neurophysiology, and genetics toward personalized medicine.

Current opinion in neurology·2026
Same journal

Editorial introduction.

Current opinion in neurology·2026
Same journal

Multimodal mapping of balance dysfunction in Parkinson's disease: a consensus roadmap for research and intervention.

Current opinion in neurology·2026
Same journal

Tourette syndrome: brain neurophysiology, circuit dysfunction, and neuromodulation across invasive and noninvasive approaches.

Current opinion in neurology·2026
Same journal

Dystonia: from phenotypes to genetics and therapeutic advances.

Current opinion in neurology·2026
Same journal

What can we learn from eye movements in movement disorders and Parkinson's disease?

Current opinion in neurology·2026
See all related articles

Area of Science:

  • Neurology
  • Genetics
  • Metabolic Disorders

Background:

  • Neurometabolic diseases encompass a range of genetic disorders affecting brain function.
  • Understanding molecular defects is crucial for diagnosis and treatment development.

Purpose of the Study:

  • To review recent advances in the molecular understanding of various neurometabolic diseases.
  • To highlight promising therapeutic strategies and the role of animal models.

Main Methods:

  • Literature review of recent studies on neurometabolic disease genetics and therapeutics.
  • Focus on specific conditions including Niemann-Pick C disease, Refsum disease, peroxisome biogenesis disorders, and Pelizaeus Merzbacher disease.

Main Results:

Related Experiment Videos

  • Molecular defects defined for Niemann-Pick C disease, Refsum disease, and five peroxisome biogenesis disorders (e.g., rhizomelic chondrodysplasia punctata).
  • Proteolipid protein gene duplication identified as common in Pelizaeus Merzbacher disease.
  • Therapies show promise for guanidinoacetate methyltransferase deficiency and 3-phosphoglycerated dehydrogenase deficiency.

    • Conclusions:

    • Significant progress in defining molecular underpinnings of rare neurometabolic disorders.
    • Development of animal models for X-linked adrenoleukodystrophy, metachromatic leukodystrophy, and Zellweger syndrome facilitates pathogenesis research and therapy evaluation.